On July 6, 2022, Chengdu XENOMIX Biotechnology Co., Ltd. (hereinafter referred to as “XENOMIX”), a wholly-owned subsidiary of Chengdu Olymvax Biopharmaceuticals Inc., and Lanzhou Bailing Bio-Tech Company Limited (hereinafter referred to as “Bailing Bio-Tech”) held a signing ceremony for the cell-based influenza vaccine project in Chengdu.
Mr. Fan Shaowen, Chairman and General Manager of OLYMVAX, and Mr. Ma Zhongren, General Manager of Bailing Bio-Tech, reached a strategic consensus on the blueprint for future cooperation. They hoped to advance the project implementation and achieve industrialization as soon as possible.
Influenza vaccine is highly seasonal and mainly applied to the elderly, the weak or young people who are prone to catching a cold. As far as the current market is concerned, the demand for cell-based influenza vaccines is growing rapidly due to their better safety. As a listed biopharmaceutical enterprise specializing in the research, development, production and sales of human vaccines, OLYMVAX has launched three varieties since its establishment. With the efficient research, development and transformation capabilities of its wholly-owned subsidiary XENOMIX and Lanzhou Bailing Bio-Tech, it is expected to accelerate the launch and production of the new influenza vaccine. The cell-based influenza vaccine project signed this time is in high demand for cut-edge technologies and featured good development prospect and strong driving effect, which marks a new step for OLYMVAX to transform from a R&D and production enterprise of bacterial vaccines to a more comprehensive enterprise for developing bacterial vaccines, viral vaccines and genetically engineered vaccines.
Project is the source of research and development. In the future, the three companies will give full play to the advantages of innovative talents and make full use of the advantages of the R&D platform of XENOMIX, a wholly-owned subsidiary of OLYMVAX to accelerate project implementation, and promote win-win cooperation among the three parties.
About Chengdu Olymvax Biopharmaceuticals Inc.
Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “OLYMVAX” or “the Company”) is a bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines. Founded in 2009, the Company was successfully listed on the Science and Technology Innovation Board of Shanghai Stock Exchange (Stock Code: 688319) on June 08, 2021, with abundant industry experts and tiered product pipelines, and outstanding scientific research and transformation capabilities. For more information, please visit www.olymvax.com.
About Chengdu XENOMIX Biotechnology Co., Ltd.
Chengdu XENOMIX Biotechnology Co., Ltd. is a wholly-owned subsidiary of Chengdu Olymvax Biopharmaceuticals Inc., specializing in the research and development of viral vaccines and monoclonal antibodies. With professional technical service equipment and professional technical team, XENOMIX has established a public technology platform for the process development and quality research of biological products in pilot scale test and commercial production, and implemented the development mode of resource sharing.
About Lanzhou Bailing Bio-Tech Company Limited
Lanzhou Bailing Bio-Tech Company Limited was established on March 09, 2010, gathering talents in various fields such as vaccine technology and animal cell culture, and mainly providing relevant technical services for vaccine enterprises.